Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/220023
Title: Incidence and determinants of COVID-19 among people who smoke (2018–2021): findings from the ITC EUREST-PLUS Spain surveys
Author: Carnicer Pont, Dolors
Fu Balboa, Marcela
Castellano, Yolanda
Tigova, Olena
Driezen, Pete
Quah, Anne C. K.
Kaai, Susan C.
Soriano, Joan B.
Vardavas, Constantine I.
Fong, Geoffrey T.
Fernández Muñoz, Esteve
Keywords: Factors de risc en les malalties
COVID-19
Hàbit de fumar
Espanya
Risk factors in diseases
COVID-19
Smoking
Spain
Issue Date: 1-Nov-2024
Publisher: Elsevier
Abstract: Objective: To estimate the cumulative incidence of COVID-19 and its determinants among a nationally representative sample of adults from Spain who smoke. Methods: This is a prospective cohort study that uses data from two waves (Wave 2 in 2018 and Wave 3 in 2021) of the ITC EUREST-PLUS Spain Survey. At baseline (Wave 1 in 2016), all respondents were adults (aged ≥18) who smoked. In total, 1008 respondents participated in Wave 2, and 570 out of 888 eligible participants were followed up in Wave 3 (64.2%). We estimated the cumulative incidence and the relative risk of COVID-19 (RR) and 95% confidence intervals (CI) during follow-up using self-reported information on sociodemographic, smoking-related and health-related characteristics and identified associated factors using multivariable Poisson models with robust variance adjusted for the independent variables. Results: The overall cumulative incidence of self-reported COVID-19 was 5.9% (95% CI: 3.9-8.0%), with no significant differences between males (6.3%; 95% CI: 3.6-9.0%) and females (5.6%; 95% CI: 3.2-8.0%). After adjusting for age, sex, and educational level, COVID-19 incidence was positively associated with moderate nicotine dependence (RR: 2.37; 95% CI: 1.04-5.40) and negatively associated with having a partner who smoked (RR: 0.12; 95% CI: 0.03-0.42), and having friends but not a partner who smoked (RR: 0.28; 95% CI: 0.14-0.56). Conclusion: The correlates of having had COVID-19 among people who smoke should be considered when tailoring information and targeted non-pharmacological preventive measures.
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.arbres.2024.05.037
It is part of: Archivos de Bronconeumologia, 2024, vol. 60, num.11, p. 690-697
URI: https://hdl.handle.net/2445/220023
Related resource: https://doi.org/10.1016/j.arbres.2024.05.037
ISSN: 0300-2896
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
891616.pdf552.83 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons